Harano, N., Liang, L. W., Hasegawa, K., Maurer, M. S., Tower-Rader, A., Fifer, M. A., Reilly, M. P., & Shimada, Y. J. (2022). Prediction of new-onset atrial fibrillation in patients with hypertrophic cardiomyopathy using proteomics profiling. European Heart Journal, 43(Supplement_2). https://doi.org/10.1093/eurheartj/ehac544.1727

Lumish, H., Liang, L. W., Hasegawa, K., Maurer, M., Tower-Rader, A., Fifer, M. A., Reilly, M. P., & Shimada, Y. J. (2022). Prediction of worsening heart failure in patients with hypertrophic cardiomyopathy using plasma proteomics profiling. European Heart Journal, 43(Supplement_2). https://doi.org/10.1093/eurheartj/ehac544.1723

Lee, C., Liang, L. W., Hasegawa, K., Maurer, M. S., Tower-Rader, A., Fifer, M. A., Reilly, M. P., & Shimada, Y. J. (2022). Proteomics profiling reveals signaling pathways associated with major adverse cardiovascular events in patients with hypertrophic cardiomyopathy. European Heart Journal, 43(Supplement_2). https://doi.org/10.1093/eurheartj/ehac544.1724

Eckhardt, C. M., Balte, P. P., Barr, R. G., Bertoni, A. G., Bhatt, S. P., Cuttica, M., Cassano, P. A., Chaves, P., Couper, D., Jacobs, D. R., Kalhan, R., Kronmal, R., Lange, L., Loehr, L., London, S. J., O’Connor, G. T., Rosamond, W., Sanders, J., Schwartz, J. E., … Oelsner, E. C. (2022). Lung function impairment and risk of incident heart failure: the NHLBI Pooled Cohorts Study. European Heart Journal, 43(23), 2196–2208. https://doi.org/10.1093/eurheartj/ehac205

OUP accepted manuscript. (2022). European Heart Journal. https://doi.org/10.1093/eurheartj/ehac266

Beohar, N., Ailawadi, G., Kotinkaduwa, L. N., Redfors, B., Simonato, M., Zhang, Z., Morgan, L. G., Escolar, E., Kar, S., Lim, D. S., Mishell, J. M., Whisenant, B. K., Abraham, W. T., Lindenfeld, J., Mack, M. J., & Stone, G. W. (2022). Impact of baseline renal dysfunction on cardiac outcomes and end-stage renal disease in heart failure patients with mitral regurgitation: the COAPT trial. European Heart Journal, 43(17), 1639–1648. https://doi.org/10.1093/eurheartj/ehac026

Tokgozoglu, L., Orringer, C., Ginsberg, H. N., & Catapano, A. L. (2022). The year in cardiovascular medicine 2021: dyslipidaemia. European Heart Journal, 43(8), 807–817. https://doi.org/10.1093/eurheartj/ehab875

Damy, T., Kristen, A. V., Suhr, O. B., Maurer, M. S., Planté-Bordeneuve, V., Yu, C.-R., Ong, M.-L., Coelho, T., & Rapezzi, C. (2019). Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS). European Heart Journal, 43(5), 391–400. https://doi.org/10.1093/eurheartj/ehz173

Gaudino, M., Di Franco, A., Alexander, J. H., Bakaeen, F., Egorova, N., Kurlansky, P., Boening, A., Chikwe, J., Demetres, M., Devereaux, P. J., Diegeler, A., Dimagli, A., Flather, M., Hameed, I., Lamy, A., Lawton, J. S., Reents, W., Robinson, N. B., Audisio, K., … Benedetto, U. (2021). Sex differences in outcomes after coronary artery bypass grafting: a pooled analysis of individual patient data. European Heart Journal, 43(1), 18–28. https://doi.org/10.1093/eurheartj/ehab504

Ginsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., Lewis, G. F., Lichtenstein, A. H., Moulin, P., Nordestgaard, B. G., Remaley, A. T., Staels, B., Stroes, E. S. G., Taskinen, M.-R., Tokgözoğlu, L. S., … Catapano, A. L. (2021). Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society. European Heart Journal, 42(47), 4791–4806. https://doi.org/10.1093/eurheartj/ehab551

Kedhi, E., Berta, B., Roleder, T., Hermanides, R. S., Fabris, E., IJsselmuiden, A. J. J., Kauer, F., Alfonso, F., von Birgelen, C., Escaned, J., Camaro, C., Kennedy, M. W., Pereira, B., Magro, M., Nef, H., Reith, S., Al Nooryani, A., Rivero, F., Malinowski, K., … Wojakowski, W. (2021). Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: the COMBINE OCT–FFR trial. European Heart Journal, 42(45), 4671–4679. https://doi.org/10.1093/eurheartj/ehab433

Escaned, J., Cao, D., Baber, U., Nicolas, J., Sartori, S., Zhang, Z., Dangas, G., Angiolillo, D. J., Briguori, C., Cohen, D. J., Collier, T., Dudek, D., Gibson, M., Gil, R., Huber, K., Kaul, U., Kornowski, R., Krucoff, M. W., Kunadian, V., … Mehran, R. (2021). Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. European Heart Journal, 42(45), 4624–4634. https://doi.org/10.1093/eurheartj/ehab702

Stefanini, G. G., Briguori, C., Cao, D., Baber, U., Sartori, S., Zhang, Z., Dangas, G., Angiolillo, D. J., Mehta, S., Cohen, D. J., Collier, T., Dudek, D., Escaned, J., Gibson, C. M., Gil, R., Huber, K., Kaul, U., Kornowski, R., Krucoff, M. W., … Mehran, R. (2021). Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. European Heart Journal, 42(45), 4683–4693. https://doi.org/10.1093/eurheartj/ehab533